Bio-Techne Corp

Bio-Techne Corp is a life sciences company that develops, manufactures, and sells purified proteins, antibodies, immunoassays, and other biotechnology tools. Its products are used in research, diagnostics, and drug discovery. The company operates through two segments: Protein Sciences (catalog and custom reagents) and Diagnostics & Genomics (clinical diagnostics and genomic analysis). Revenue is primarily generated from the sale of reagents, kits, and instruments to academic, government, and pharmaceutical customers. The Protein Sciences segment contributes the majority of revenue, with a focus on high-margin, proprietary products.

Bio-Techne operates in the highly competitive biotechnology tools and reagents industry, competing with companies like Thermo Fisher, Danaher, and Abcam. It differentiates itself through a deep portfolio of high-quality proteins and antibodies, particularly in the areas of cytokines, growth factors, and neuroscience. The company holds a strong position in the research reagent market, with a reputation for product consistency and technical support. Its gross margin of 64.8% reflects the value-added nature of its products.

Customers include academic research institutions, biopharmaceutical companies, clinical diagnostic laboratories, and government agencies. Bio-Techne’s products are used in basic research, translational medicine, and clinical testing. Geographically, the company generates about 60% of revenue from the United States, with the remainder from Europe, Asia Pacific, and other regions. The Diagnostics & Genomics segment has a growing presence in clinical diagnostics, particularly in blood coagulation and autoimmune disease testing.

Financially, Bio-Techne has a market cap of $8.14 billion and trades at a high P/E of 75.35, reflecting its growth expectations. The company has low debt of $200 million against $210 million in cash, and generates positive free cash flow with a 3.89% yield. Recent quarterly revenue has been stable around $300 million, with a notable net loss in Q2 2025 due to impairment charges, but profitability has since recovered. The dividend yield is modest at 0.61%.

An auto-generated descriptive profile based on company data, for informational purposes only.